Clinuvel Pharmaceuticals (UR9) Stock Statistics & Valuation Metrics

Clinuvel Pharmaceuticals has a market cap or net worth of CHF264.57M. The enterprise value is CHF398.04.

Clinuvel Pharmaceuticals has 50,427,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Clinuvel Pharmaceuticals ’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 13.10%.

The current PE Ratio of Clinuvel Pharmaceuticals is 13.9. Clinuvel Pharmaceuticals ’s PEG ratio is 0.00.

In the last 12 months, Clinuvel Pharmaceuticals had revenue of 95.02M and earned 36.17M in profits. Earnings per share was 0.72.

In the last 12 months, operating cash flow was 40.47M and capital expenditures -390.18K, giving a free cash flow of 40.08M billion.

Clinuvel Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Clinuvel Pharmaceuticals upcoming earnings date is Sep 1, 2026, TBA (Confirmed).

Clinuvel Pharmaceuticals as a current ratio of 9.66, with Debt / Equity ratio of 0.14%

In the past 12 months, Clinuvel Pharmaceuticals has paid 15.38M in taxes.

Clinuvel Pharmaceuticals EV to EBITDA ratio is 5.18, with an EV/FCF ratio of 7.26.

Clinuvel Pharmaceuticals has CHF233.00M in cash and marketable securities with CHF341.09K in debt, giving a net cash position of CHF232.66M billion.

Gross margin is 63.71%, with operating margin of 48.13%, and net profit margin of 38.07%.

The average price target for Clinuvel Pharmaceuticals is CHF16.43, which is 11.43% higher than the current price. The consensus rating is Moderate Buy